NRX Pharmaceuticals Free Cash Flow (FCF) History (NRXP)

NRX Pharmaceuticals reported −$10.6M in free cash flow for fiscal 2024, an increase of $11.0M from the previous fiscal year.

View full NRX Pharmaceuticals company overview

NRX Pharmaceuticals free cash flow by year

NRX Pharmaceuticals annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-12-31−$10.6M$11.0M
20232023-12-31−$21.7M$18.1M
20222022-12-31−$39.8M−$2.1M
20212021-12-31−$37.7M−$35.4M
20202020-12-31−$2.3M

NRX Pharmaceuticals free cash flow growth trends

NRX Pharmaceuticals's latest reported quarter, Q1 2025, generated −$3.5M in free cash flow, an increase of $191,000 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review NRX Pharmaceuticals filings at SEC.gov ↗